Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Pilot -Not Accredited)

 

The measurement of measurable residual disease (MRD) populations is often performed following treatment for leukaemic disorders. The levels are used as a predictive factor for relapse or an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.

 

This programme issues stabilised whole blood into which has been spiked some stabilised plasma cell myeloma material. Laboratories are required to determine the level of measurable residual disease by flow cytometry, please note this programme is not suitable for the measurement of MRD by molecular methods.

 

The programme issues a presentation sample together with 2 follow up samples. Please note that the presentation sample will not contain the expected level of disease seen in a typical clinical scenario. The 2 follow up samples are manufactured from the same plasma cell myeloma case and are designed to represent different stages post treatment to assess the ability of a centre to detect B plasma cell myeloma cells at minimal residual disease levels within a background of stabilised normal whole blood. Laboratories are requested to report the percentage of residual neoplastic plasma cells in the 2 follow up samples as a percentage of the plasma cell population.

 

Three samples are issued per trial and this programme issues samples a minimum of 2 times per annum.

 

Trials for this programme are live/open for a minimum of 3 weeks.

Please Note: Trials issued/closing in August or December are extended by 1 week.

An automated email is sent 2 days prior to the trial closing, to any participant that has not returned results, warning them of the trial closure date. 

 

 ***NEW IN 2024-2025*** 
UK NEQAS LI have ongoing issues sourcing patient samples for this programme. If you are able to provide samples, please contact admin@ukneqasli.co.uk and we would be happy to organise consent and shipping. As a result of this 2024/2025 rounds in this programme may be electronic or sample based. 

 

No activities in relation to this EQA programme are subcontracted.

 

To register for this programme, please click here.

Example Measurable Residual Disease for PCM by Flow Cytometry (Not Accredited) Report
MRD PCM Example Report.pdf
Adobe Acrobat document [1.3 MB]
MRD PCM 232402 Coversheet
MRD PCM 232402.pdf
Adobe Acrobat document [357.5 KB]
Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 16/05/2024 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.


Please click here for our privacy policy.


The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).